Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 787
The Licensee shall have a research License, with the right to grant sublicenses solely in order to test internally or through sub-contractors up to three hESC Lines (HADC100, HADC102 and HADC106) and three Feeder Lines of the Materials prior to the selection of the Licensed Materials, which Research License shall expire upon the selection by the Company of the Licensed Materials, in respect of all other Materials.
The hESC are being provided for use as a source material for a therapeutic product and Hadasit has no reason to believe that the hESC and feeder cell lines, if used by the Company in accordance with regulatory guidelines, are not consistent with such use.
One WCB of cord feeder cell line that will include a minimum of 40 vials (with a minimum of 5X106 per vial or equivalent) and additional 10 vials (with a minimum of 2.5×106 per vial) will be provided and shall be replication incompetent, meaning irradiated. The specified number of vials is before any characterization and safety testing
Five ampoules of 2 x 106 cells/ampoule of WCB cord feeders, which have not been irradiated or blocked by mitomycin C and are at passage earlier than ten (10) and are from the same MCB from which the irradiated WCB was developed will be provided. As part of the companyâ€™s OCS 2010 or OCS 2011 project or other funding source, the Company will cover all costs related to the preparation of the WCB from which these five ampoules will originate and the characterization of the WCB according to the recommendations of FDA consultant .
The Company is engaged in the development and commercialization of cell therapy applications for neurodegenerative diseases.
IPSCIO Record ID: 213949
IPSCIO Record ID: 6977
Licensor hereby grants Licensee and its Affiliates a world-wide, nonexclusive license under the Licensed Patents and the Licensed Materials to develop, use, provide, and sell Services in the Licensed Field.
Licensor hereby grants Licensee and its Affiliates a world-wide, nonexclusive license under the Licensed Patents and the Licensed Materials to make, develop, use, sell, offer for sale, and import Research Products in the Licensed Field. The grants of this Section 2A shall only apply to those Affiliates for which Licensee has provided written notice to Licensor. Any such identified Affiliates benefiting from such grants shall be bound by all obligations under this Agreement.
Limited Sublicenses – Licensor hereby grants Licensee the right to grant written limited sublicenses under the Licensed Patents to transfer, as applicable, Licensed Materials and/or Derivative Materials to Collaborators, Development Partners and Contract Service Providers, in accordance with the terms of this agreement.
Title – Countries – Issued Patents (U.S.)
Primate Embryonic Stem Cells – US; EP; CA; WO – 7,029,913 5,843,780 6,200,806.
Serum-Free Cultivation of Primate ES Cells – US; AU; BR; CA; CN; EP; HK; IL; IN; IS; JP; KR; MX; NO; NZ; SG – 7,217,569 7,005,252.
Master Human Stem Cell Lines for Gene Expression and Knockdown – US.
Methods Of Making Differentiated Cells From Primate Embryonic Stem Cells – US.
Differentiation of Stem Cells to Endoderm and Pancreatic Lineage – US.
Hematopoietic Differentiation of hESCs – AU; BR; CA; CN; EP; IL; IN; IS; JP; KR; LU; MX; NO; NZ; SE; SG; US; WO – 6,280,718 6,613,568.
Method of In Vitro Differentiation of Transplantable Neural Precursor Cells From Primate ES Cells – US – 6,887,706.
Endothelial Cells Derived from Primate ES Cells – AU; CA; CN; EP; HK; IL; IN; IS; JP; KR; LU; MX; NZ; SE; SG; US – 7,176,023.
Method of Making Embryoid Bodies from Primate ES Cells – US; AU; BR; CA; CN; EP; HK; IL; IN; IS; JP; KR; MX; NO; NZ; SG – 7,220,584 6,602,711.
Method of Forming Mesenchymal Stem Cells from ES Cells – AU; CA; EP; GB; IL; JP; KR; SG; US.
Directed Differentiation of hESCs into Mesenchymal/Stromal Cells – US.
In Vitro Differentiation of Hematopoietic Cells from Non-Human Primate and Human ES Cells – US; WO.
Generation of Clonal Mesenchymal Cells from hESCs in Serum-Free Conditions – US.
Cryopreservation of Pluripotent Stem Cells – US.
Defined Surfaces Of Self-Assembled Monolayers And Stem Cells – US.
Method of Reducing Cell Differentiation – US.
Improved Culture Of Stem Cells – US; WO.
Physiological Culture Conditions for ES Cells – US.
Feeder-Independent Extended Culture of ES Cells – AU; CA; CN; EP; GB; IL; IN; IS; JP; KR; NZ; SE; SG; US.
Cultivation of Primate ES Cells – AU; CA; CN; EP; GB; IL; JP; KR; SG; US.
Directed Genetic Modifications of Human Stem Cells – AU; CA; EP; GB; IL; KR; SG; US.
Method for Generating Primate Trophoblasts – AU; CA; CN; EP; HK; IL; IN; IS; JP; KR; MX; NZ; SG; US – 7,148,062.
Method of In Vitro Differentiation of Neural Stem Cells, Motor Neurons, and Dopamine Neurons from Primate ES Cells – US.
Method of Forming Dendritic Cells from ES Cells – AU; EP; GB; IL; JP; KR; SE; SG; US.
Differentiation of Pluripotent ES Cells – US.
Method of Generating Myelinating Oligodendrocytes from ES Cells – US.
A Method for Generating Keratinocytes and Keratinocyte Precursors from hESCs – US.
Licensed Materials means primate (including human) embryonic stem cells covered by the valid claims in the Licensed Patents and which meet the following conditions
(i) For embryonic stem cells created prior to April 26, 2005, the embryonic stem cell must be either (1) listed on the NIH Human Embryonic Stem Cell Registry at http//escr.nih.gov; or (2) derived from excess embryos created for the purpose' of in vitro fertilization with appropriate consent of the donor couple and not for the purpose of creating embryonic stem cells; or (3) derived from embryos created specifically for research purposes either by in vitro fertilization or by somatic cell nuclear transfer, for which the following additional conditions apply (a) the embryo may not have been maintained in vitro for more than 14 days; (b) the gamete donor(s) and somaticcell donor (if any) made the donation without payment beyond reimbursement for reasonable expenses associated with donation; (c) in the case of egg donation, the donor was fully informed of the risks to herself; (d) the gamete donor(s) and somatic cell donor (if any) were fully informed of the purposes to which their donated materials would be put; (e) the research could not be done equally weU using surplus IVF embryos originally created for reproductive purposes; (f) the research protocol, including gamete collection, somatic cell collection, embryo management and stem cell derivation is approved by an appropriate Institutional Review Board; and (g) protections are in place to prevent misappropriation of embryos created specifically for research.
(ii) For embryonic stem cells created from embryos created after April 26, 2005, the embryonic stem cells must be derived from embryos and under conditions in compliance with the Guidelines for Human Embryonic Stem Cell Research established by the National Research Council Institute of Medicine of the National Academies (the NAS Guidelines).
(iii) For embryonic stem cells created after April 26, 2005 from embryos generated prior to April 26, 2005, and which do not meet the NAS Guidelines, the embryonic stem cells must meet one of the conditions set forth in paragraph (i) above and be created using protocols substantially in compliance with the requirements of the NAS Guidelines.
IPSCIO Record ID: 168
Company granted an exclusive license to use its â€œACTCellerateâ€ embryonic stem cell technology and a bank of over 140 diverse progenitor cell lines derived using that technology.
The licensed rights include pending patent applications, knowledge and the existing bank of cell lines. The licence is exclusive and worldwide for all commercial purposes, including the development of research products, and therapeutic and diagnostic products for human and veterinary use. Licensor has an option to reacquire rights to use the technology for the development of certain types of SCs for human therapeutic use in fields re-lated to its core business.
The technology allows the rapid isolation of novel, highly-purified embryonic progenitor cells. The progenitor cells are relatively easy to manufacture on a large scale and in a purified state, which may make it advantageous to work with these cells compared to the direct use of ESCs. These unique cell lines may have potential applications in research, drug discovery and human regenerative SC therapy.
103080-069-WO1 (PCT/US06/13519, filed on 4-11-06) Novel uses of cells with Prenatal Patterns of prenatal gene expression, published as WO2007/058671
103080-071-P61 (USSN 60/791,400, filed on Apr. 11, 2006) Methods to accelerate the isolation of novel cell strains from pluripotent ST
103080-071-P66 (USSN 60/850,294, filed on Oct. 6, 2006), Methods to accelerate the isolation ov novel cell strains from pluripotent stem cells
103080-071-P01 (USSN 11/604,047, filed on Nov. 21, 2006), Methods to accelerate the isolation of novel cell strains from pluripotent STE…
PCT is 103080-071-WO2 (PCT/US2006/45352, filed on Nov. 21, 2006), published as WO 2007/062198.